Tag Archive for: Novo

Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health

With the agreement, the Foundation expands its existing collaboration with WHO, committing to a granting frame of up to DKK 380 million over the next four years. At the 78th World Health Assembly in Geneva, the Novo Nordisk Foundation has pledged up to DKK 380 million to the WHO for the period 2025-2028. The Foundation […]

Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities

May 15, 2025 – Novo Holdings is pleased to announce the appointments of Jun Sung Kim, Lars Green, N.P. “Narv” Narvekar and Torsten Sløk to its Board of Directors, effective May 14, 2025. These distinguished leaders bring a broad range of investment expertise spanning both U.S. and international markets, further strengthening the Board’s global perspectives […]

Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants

Copenhagen, Denmark: The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK, to lead collaborations applying for grants to study four major themes. As part of its ongoing internationalisation, the […]

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies

Copenhagen, Denmark – Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of […]

QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024

– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks Beijing, China, 12 September 2024 – Beijing QL […]